Hepatab 200

Generic

Rifaximin

 

Indications

Rifaximin is indicaed in-

• Treatment of traveler's diarrhea by noninvasive strains of E. coli
• reduction in risk of overt hepatic encephalopathy
• bacterial overgrowth of irritable bowel syndrome.

 

Pharmacology

Rifaximin could be a semisynthetic, rifamycin-based non-systemic anti-microbial. Exceptionally small of the medicate will pass the gastrointestinal divider into the circulation as is common for other sorts of orally managed anti-microbials. Rifaximin represses bacterial RNA amalgamation by its activity on the beta-subunit of the DNA-dependent RNA polymerase. It appears the same wide range movement as rifamycin which applies bactericidal activity against numerous species of Gram-positive and Gram-negative, high-impact and anaerobic microbes.

 

Dosage & Administration

Traveler's Diarrhea: For patients ≥12 years of age: 200 mg 3 times daily for 3 days.
Hepatic Encephalopathy: For patients ≥18 years of age: 550 mg 2 times daily.
Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food

 

Interaction

In an in vitro study has suggested that Rifaximin induces CYP3A4. However, in patients with normal liver function, Rifaximin at the recommended dosing regimen is not expected to induce CYP3A4.

 

Contraindications

Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product

 

Side Effect

Side effects include flatulence, headache, abdominal pain, rectal tenesmus, defecation urgency, nausea, constipation, pyrexia, vomiting. Reactions have been reported, including anaphylaxis, angioneurotic edema, and exfoliative dermatitis.

 

Pregnancy & Lactation

Pregnancy category C. It is not known whether Rifaximin is excreted in human milk or not.

 

Precautions & Warnings

Rifaximin isn't found to be viable in patients with loose bowels complicated by fever and/or blood within the stools. Rifaximin treatment ought to be ceased in the event that loose bowels indications get more regrettable or hold on for more than 24-48 hours and elective anti-microbial treatment ought to be considered. Pseudomembranous colitis has been detailed with about all antibacterial operators and may extend in seriousness from mellow to life-threatening. Hence, it is vital to consider this determination in patients who show with loose bowels ensuing to the organization of antibacterial specialists.

 

Therapeutic Class

4-Quinolone preparations

 

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

 

Pharmaceutical Name

Ibn Sina Pharmaceuticals Ltd.